Unlike E2A-PBX1 and TEL-AML1 rearrangements, which could be used to predict therapeutic responses, leukemias with MLL1 fusions poorly responded to most chemotherapies and had a dire prognosis [138]. Here, KMT2A is linked to leukemia.